• Target disease: Visceral leishmaniasis
  • Main Partners (since project start): AbbVie, USA; BioAster, France; Centre for Drug Candidate Optimisation, Monash University, Australia; Epichem, Australia; Eurofins CEREP, France; Eurofins Pharma Discovery Services (formerly Eurofins Panlabs), USA; Griffith Institute for Drug Discovery (GRIDD), Griffith University, Australia; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene and Tropical Medicine, UK; WuXi AppTech, China.
  • Project start: 2017
  • Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Swiss Agency for Development and Cooperation (SDC), Switzerland.


Overall Objective: 

  • Progress a compound from the 205 series towards candidate selection and nomination for further pre- clinical development for VL.


Following proof-of-principle with the 205 series for VL, compounds from this series have shown a 100% parasite load reduction in liver and spleen in a VL murine model. Further characterization of this series is ongoing. Over 400 compounds have been synthesized to date in this lead optimization programme for Chagas disease and leishmaniasis.




Last update: August 2018